TIAA CREF Investment Management
MYOK

TIAA CREF Investment Management’s MyoKardia, Inc. Common Stock MYOK Stock Holding History

TIAA CREF Investment Management’s Portfolio MYOK Stock Details MYOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$5.41M Sell
103,990
-1,805
-2% -$83.2K ﹤0.01% 1397
2018
Q4 		$5.17M Buy
105,795
+950
+0.9% +$52.3K ﹤0.01% 1355
2018
Q3 		$6.84M Buy
104,845
+29,722
+40% +$1.75M ﹤0.01% 1364
2018
Q2 		$3.73M Sell
75,123
-100,259
-57% -$4.85M ﹤0.01% 1811
2018
Q1 		$8.56M Buy
175,382
+2,313
+1% +$120K 0.01% 1208
2017
Q4 		$7.29M Buy
173,069
+21,338
+14% +$822K ﹤0.01% 1367
2017
Q3 		$6.5M Buy
151,731
+49,448
+48% +$1.58M ﹤0.01% 1459
2017
Q2 		$1.34M Buy
102,283
+67,827
+197% +$894K ﹤0.01% 2403
2017
Q1 		$453K Sell
34,456
-6,900
-17% -$88.4K ﹤0.01% 2824
2016
Q4 		$536K Sell
41,356
-3,625
-8% -$55.8K ﹤0.01% 2815
2016
Q3 		$735K Sell
44,981
-2,204
-5% -$39.8K ﹤0.01% 2698
2016
Q2 		$585K Buy
47,185
+39,412
+507% +$493K ﹤0.01% 2794
2016
Q1 		$83K Buy
+7,773
New +$70.7K ﹤0.01% 3040

Other funds holding MYOK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Farallon Capital Management
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
BB Biotech
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

TIAA CREF Investment Management's MYOK Position: Q1 2019 in Review

TIAA CREF Investment Management reduced its MyoKardia, Inc. Common Stock (MYOK) stake by 1.7% in Q1 2019, selling an estimated $83.2K and leaving 103,990 shares worth $5.41M. The position accounts for ﹤0.01% of the portfolio, ranked #1397.

TIAA CREF Investment Management first reported a position in MYOK in Q1 2016 and has held it in 13 quarters since. The position peaked at $8.56M in Q1 2018. 169 funds tracked by Wall St. Rank hold MYOK as of Q1 2019.

  • TIAA CREF Investment Management held 103,990 shares of MyoKardia, Inc. Common Stock worth $5.41M as of Q1 2019.
  • TIAA CREF Investment Management sold 1,805 MyoKardia, Inc. Common Stock shares in Q1 2019, an estimated $83.2K.
  • MyoKardia, Inc. Common Stock made up ﹤0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #1397 holding.
  • TIAA CREF Investment Management first reported a position in MyoKardia, Inc. Common Stock in Q1 2016 and has held it in 13 quarters since.
  • TIAA CREF Investment Management's MyoKardia, Inc. Common Stock position peaked at $8.56M in Q1 2018.
  • 169 funds tracked by Wall St. Rank held MyoKardia, Inc. Common Stock as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.